Tag: biotech partnerships
-
ImmunoForge to Host Partnering Meetings at JPM 2026 Conference
ImmunoForge Sets the Stage for Global Licensing at JPMorgan Healthcare Conference 2026 ImmunoForge Co., Ltd. announces a strategic push at the 2026 JPMorgan Healthcare Conference in San Francisco, focusing on global out-licensing of its Phase 2 assets PF1801 and PF1804. With co-CEOs and a mission to accelerate clinical progress, ImmunoForge plans to engage directly with…
-
Tiger BioSciences Spotlight: Major Clinical and Scientific Milestones After 2025 Research Investment
Tiger BioSciences today highlights a year of pivotal progress across its clinical programs and scientific initiatives, driven by a renewed emphasis on evidence-based research and strategic investments in 2025. The company’s leadership says the expanded funding and collaborative approach have accelerated the translation of laboratory insights into patient-centered outcomes, reinforcing its position at the forefront…
-
Galux and Boehringer Ingelheim Partner on AI Protein Design
Galux Collaborates with Boehringer Ingelheim to accelerate AI-driven protein design South Korea’s Galux, a biotech startup focused on AI-powered protein therapeutics discovery, has entered a strategic research agreement with Boehringer Ingelheim. The collaboration aims to explore and advance artificial intelligence technologies that can design novel protein therapeutics with improved efficacy, safety, and development timelines. The…
-
Innovent Highlights: General Biomedicine Pipeline Showcased at 2025 ACR Annual Meeting
Innovent Unveils Progress Across the General Biomedicine Pipeline at the 2025 ACR Annual Meeting The 2025 ACR Annual Meeting in San Francisco and nearby venues became a hub for researchers and industry leaders as Innovent Biologics, a global biopharmaceutical company, highlighted several milestones from its General Biomedicine Pipeline. The presentations underscored a commitment to advancing…
-
Knut Steffensen Drives Cell and Gene Therapy From Lab to Patients at Karolinska
From Lab to Patient: Turning Cell and Gene Therapy into Real Treatments Knut Steffensen is taking on the ambitious task of steering cell- and gene-based therapies from the research bench into routine patient care at Karolinska. As head of the university’s ATMP-Centre, he faces the challenge of coordinating the many moving parts required to translate…